Contact us

Support


Kedrion S.p.A

The Russian pharmaceutical producer Pharmstandard, National Immunobiological Company (Nacimbio, part of Rostekh) and the Italian pharmaceutical company Kedrion Biopharma have become founders of Kirov Plasma JSC, located on the territory of the unfinished Kirov plant for the production of blood products Rosplazma. The Government of the Kirov region reports that the corresponding agreement was signed on Thursday in Moscow.

23 March 2017
RIA Novosti

National Immunobiological Company (state-owned corporation Rostech) signed an agreement with Italian Kedrion on the establishment of a joint venture on the bases of the Kirov complex and on transfer of technology as well as on the purchase from Belarus Farmland of a share in the Minsk enterprise producing human plasma preparations. The total project investment amount will be over 5.5 bln rubles. The site in Minsk will be launched in 2018 and will be capable of processing 150 tonnes of plasma per annum with further increase to 450 tonnes. The production in Kirov will begin in 2019 and will process 600 tonnes of plasma.

“Kedrion Biopharma is very proud of the agreement we signed today”, said Head of Kedrion Biopharma Paolo Marcucci. “It reflects the wish of our company to support national healthcare systems both as a partner and as a supplier of technology and services. The active role of Nacimbio in ensuring the national security of the Russian Federation in production of vital drugs is very close to Kedrion. Since the start of our activities we were a partner of the Italian healthcare system in the program aimed at availability of plasma preparations”.

17 June 2016
http://www.pharmvestnik.ru/
Investor
Kirov Region

Investor profile

Kedrion S.p.A

Italy

Company's website: http://www.kedrion.com/

T: +39 0583 19691

Public company

Contact: Paolo Marcucci, Director General

Kedrion Biopharma is an international company which is engaged in collection and separation of blood plasma and production of preparations aimed at the treatment of such diseases as hemophilia and immune disorders.

Subscribe to Newsletters

Email: